CDKN2A and neoplasm: Recent advances in gene sequence technology and transcriptome analyses revealed that MPM cells have mutations in tumor-suppressor genes, such as BAP1, NF2, RASSF1, LATS2WT1, p16, TP53, and CDKN2A, whereas it is not clear molecular targeting strategy is effective for the eradication of MPM cells (25–27).